Compare DCBO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | OVID |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.6M | 365.5M |
| IPO Year | 2020 | 2017 |
| Metric | DCBO | OVID |
|---|---|---|
| Price | $20.61 | $2.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $4.60 |
| AVG Volume (30 Days) | 119.7K | ★ 3.0M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $12.89 | N/A |
| Revenue Next Year | $11.44 | $19.34 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $14.39 | $0.27 |
| 52 Week High | $33.69 | $3.11 |
| Indicator | DCBO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 60.07 |
| Support Level | $20.20 | $2.56 |
| Resistance Level | $22.96 | $3.11 |
| Average True Range (ATR) | 1.03 | 0.15 |
| MACD | 0.40 | -0.03 |
| Stochastic Oscillator | 95.87 | 55.68 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.